IRCT201104116168N1Completed未知
Buspirone versus Methylphenidate in 6-16 aged children with Attention Deficit/Hyperactive Disorder(ADHD). A crossover study
euroscience Research Center Kerman University of Medical Sciences, Kerman ,Iran0 sites40 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 40
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 6 years to 16 years (—)
- Sex
- All
Inclusion Criteria
- •ADHD diagnosis according to DSM-IV-TR criteria that scored above 20 in ADHD-Rating Scale. Exclusion criteria: evidence of a mental retardation(IQ<70) or a major psychiatric problem other than oppositional defiant disorder and conduct disorder or receiving any psychotropic medication through 2 weeks before initiating treatment; medical disorders that would preclude the safe use of methylphenidate or buspirone.
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Recruiting
Phase 2
Effect of Buspirone in ADHDAttention deficit/hyperactivity disorder.Attention-deficit hyperactivity disordersIRCT20160530028182N7Sanandaj University of Medical Sciences50
Completed
Phase 2
Buspirone in ADHDAttention Deficit Hyperactivity Disorder.Disturbance of activity and attentionIRCT138901292000N3Behavioral Sciences and Research Center of Shahid Beheshti University of Medical Sciences.34
Not yet recruiting
Not Applicable
Methylphenidate for ADHD in Smith-Magenis syndromeSmith-Magenis syndromeADHDNL-OMON20117Amsterdam UMC6
Recruiting
Not Applicable
Effectiveness of methylphenidate in children and adults with Smith Magenis syndrome and attention-deficit/hyperactivity disorder: An N-of-1 seriesNL-OMON52697Academisch Medisch Centrum6
Active, not recruiting
Phase 1
Methylphenidate in KBG syndromeCTIS2023-506202-40-01Stichting Radboud University Medical Center15